Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Awad

Showing results (151-160 of 210) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLCSeshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Jieun Son, Jeffrey J Okoro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing ProgramBrittany L Bychkovsky, Tianyu Li, Jilliane Sotelo, et al.
Cancer Discovery|April 15, 2017
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung CancerDennis O Adeegbe, Yan Liu, Patrick H Lizotte, et al.
JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung CancerPatrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
JAMA Oncology|November 29, 2016
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)Paul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain MetastasesPaul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
Pageof 21

Showing results (151-160 of 210) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLCSeshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Jieun Son, Jeffrey J Okoro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing ProgramBrittany L Bychkovsky, Tianyu Li, Jilliane Sotelo, et al.
Cancer Discovery|April 15, 2017
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung CancerDennis O Adeegbe, Yan Liu, Patrick H Lizotte, et al.
JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung CancerPatrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
JAMA Oncology|November 29, 2016
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)Paul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain MetastasesPaul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
Pageof 21